Naibec Confirms Potential to Regenerate Jawbone and Tooth Supporting Tissue
Predicted impact: Low
Early preclinical finding on tissue regeneration; far from commercial revenue, vague impact.
Nibec나이벡
138610 · KOSDAQ · ₩138610 · 나이벡
₩14,580▲ ₩20 (0.14%)End-of-day · Oct 27, 2026 · End-of-day prices.
Price · 1Y −65.04%
- Market cap
- ₩166B
- Enterprise value
- ₩152B
- P/E
- —
- P/B
- 3.5×
- Dividend yield
- 0.0%
- ROE
- −5.6%
- Net margin
- −11.9%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−73.1% from the high
₩11,230Today: ₩14,400 – ₩14,950₩54,300
Returns
- 1W−5.8%
- 1M−4.6%
- 3M+9.7%
- 6M−46.4%
- YTD−61.2%
- 1Y−65.0%
- Volume today
- 22,231
- 0.6× the 20-day average
- Traded today
- ₩326M
- Listed shares
- 11,368,297
- EPS (12 months)
- −₩238
- Earnings yield −1.6%
AI research · InitiationNibec: Revenue Recovered in 2025, but Losses Returned in the Latest Twelve Months and the Share Price Is Down 67.0% Over a YearThe data shows a company with growing revenue over five years but an unstable profit record: one profitable year in 2025 followed by trailing losses.Read the full report →
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 37 of 100 (50 is a normal day for this stock).
- MomentumFlat-4% over the last month; the price is below its 20-day average.
- News impactLow2 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
Nibec stock overview
Nibec (나이벡, KRX: 138610) is listed on KOSDAQ, in the Biotech & Pharma sector. The company develops and sells regenerative biomaterials for dental and tissue repair, including collagen-based dental grafting materials sold worldwide through major implant makers, and is developing peptide-based regenerative drug candidates for fibrosis, obesity, sarcopenia, and periodontitis, along with oral health products. Its shares closed at ₩14,580 on Oct 27, 2026, up 0.14% on the day, giving it a market value of ₩166B.
Key facts
- Market cap
- ₩166B
- Sector
- Biotech & Pharma
- Latest price change
- +0.14%
- As of
- Oct 27, 2026
- Main business
- The company develops and sells regenerative biomaterials for dental and tissue repair, including collagen-based dental grafting materials sold worldwide through major implant makers, and is developing peptide-based regenerative drug candidates for fibrosis, obesity, sarcopenia, and periodontitis, along with oral health products.
Quick answers about Nibec
- What does Nibec do?
- The company develops and sells regenerative biomaterials for dental and tissue repair, including collagen-based dental grafting materials sold worldwide through major implant makers, and is developing peptide-based regenerative drug candidates for fibrosis, obesity, sarcopenia, and periodontitis, along with oral health products. Its dental biomaterials are marketed internationally, with regulatory approvals in regions including China and the European Union.
- What is the market cap of Nibec?
- The market capitalisation of Nibec was ₩166B at the close on Oct 27, 2026.
- Who are the largest shareholders of Nibec?
- According to the latest official filings, the largest reported holders are Park Yun-jeong (3.26%, as of Aug 5, 2026); National Pension Service (0.84%, as of Dec 31, 2025); EMERGING MARKETS CORE EQUITY 2 PORTFOLIO (0.07%, as of Jul 31, 2026).
- When is the next earnings report from Nibec?
- Korean companies rarely announce results dates in advance. Based on when Nibec filed the same report in past years, its next 3q results is expected between Nov 13, 2026 and Nov 14, 2026.
- Does the National Pension Service own Nibec?
- Yes. The National Pension Service held 0.84% of Nibec shares as of Dec 31, 2025.
Company profile
The company develops and sells regenerative biomaterials for dental and tissue repair, including collagen-based dental grafting materials sold worldwide through major implant makers, and is developing peptide-based regenerative drug candidates for fibrosis, obesity, sarcopenia, and periodontitis, along with oral health products. Its dental biomaterials are marketed internationally, with regulatory approvals in regions including China and the European Union.
Written by AI from the company's latest annual report.
- Korean name
- 나이벡
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 정종평
- Founded
- Feb 2004
- Listed
- Jul 2011
- Listed shares
- 11,368,297
- Fiscal year ends
- Month 12
- Website
- -
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent news
Nyvec confirms potential to alleviate kidney and heart fibrosis, unveils preclinical data at US conference
Predicted impact: Low
Preclinical data at a conference is early-stage and vague for valuation.
Recent filings
See all- Acquisition of Convertible Bonds (Including Overseas Convertible Bonds) After Issuance and Before MaturityAug 24, 2026
- Half-year report (Jun 2026)Aug 14, 2026
- Insider shareholding reportAug 5, 2026
- Investor relations (IR) eventMay 18, 2026
- Quarterly report (Mar 2026)May 14, 2026
Titles in Korean until English translations are added.
Also known as: Nibec / 나이벡 / 138610 / KRX:138610
Source: KRX statistical information